Needham & Company Maintains a 'Buy' on Optimer Pharmaceuticals (OPTR); Q2 Preview

Needham & Company maintains a 'Buy' on Optimer Pharmaceuticals (NASDAQ: OPTR).

Analyst, Alan Carr, said, "Optimer is expected to announce 2Q12 financial results on 7/31/12. Our 2Q12 Dificid net sales estimate is $18.0M (was $19.0M), based on updated IMS data. The company reported $14.4M in Dificid net sales in 1Q12. Optimer announced in May 2012 that the company expects to exceed the first year sales target under the Cubist commercialization deal, which would trigger a $5M incentive payment and profit split...Collaborator Astellas (OTC: ALPM) launched Dificlir in Europe in June 2012, triggering a €10M milestone payment to Optimer. This payment was recognized in 4Q11. The drug was approved in Canada in July 2012, where it will be marketed by Optimer’s sales force."

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $15.19 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Diana Shipping withdraws bid to acquire Genco Shipping
• Diana Shipping drops bid for Genco after price demands spike to $36.91